Fragile X Syndrome (FXS)IMAGINERNCT06868979
Optical Imaging in X-linked Disorders.
A study testing Clinical assessment, Parental questionnaires and Cognitive assessment in people with Fragile X Syndrome (FXS) and Creatine Transporter Deficiency, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Fragile X syndrome (FXS, OMIM #300624) and Creatine Transporter Deficiency (CTD, #300352) are the two most common causes of X-linked intellectual disability. FXS and CTD affect hemizygous males and with highly variable severity heterozygous females. Read more about this study
- Who is it for?
- Ages 5 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Fragile X Syndrome (FXS), Creatine Transporter Deficiency
- What is being tested?
- Clinical assessment, Parental questionnaires and Cognitive assessment
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 118 participants
- Where
- 1 siteFrance
- Study dates
- 30 Mar 2026to Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 60 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- CTD male patients :
- male
- having a confirmed mutation in the SLC6A8 gene
- ≥ 5 to ≤ 35 years old
- whose maternal language is French,
- having signed the informed consent and/or for whom parents (for children)/legal guardian (for protected adults) have signed the informed consent.
Show all 33Show fewer
- affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
- CTD female patients :
- female CTD patients having a confirmed mutation in the SLC6A8 gene,
- aged > 5 to < 60 years,
- whose maternal language is French (for the patients included in France),
- having signed the informed consent and/or for whom parents (for children)/legal guardian (for protected adults) have signed the informed consent.
- affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
- FXS patients :
- male
- having a confirmed full mutation in the FMR1 gene (>200 GCC repeats)
- ≥ 5 to ≤ 35 years old
- whose maternal language is French,
- having signed the informed consent and/or for whom parents (for children)/legal guardian (for protected adults) have signed the informed consent.
- affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
- Sex- and chronological age-matched male controls :
- male
- ≥ 5 to ≤ 35 years old
- whose maternal language is French,
- having signed the informed consent and/or for whom parents have signed the informed consent.
- affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
- Sex- and chronological age-matched female controls :
- female,
- aged > 5 to < 60 years
- whose maternal language is French (for the patients included in France),
- having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent.
- affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system.
- Each CTD patient will be matched to a sex- and chronological age-matched control.
Who cannot join
- CTD male and female patients :
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
- Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.
- FXS patients :
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
- Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.
Show all 12Show fewer
- Sex- and chronological age-matched male and female controls :
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
- Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.
- History of neurological or psychiatric disorder,
- Repetition of a grade,
- Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Woman, mother and child hospital, Hospices Civils de Lyon
Bron, 69500
Aurore Curie, Dr, +33 6 70 62 69 76, Aurore.curie@chu-lyon.fr
Aurore Curie, Dr
About this study
Official title: Optical Imaging as a Diagnostic Tool for Monitoring Brain Function in X-linked Rare Disorders
Fragile X syndrome (FXS, OMIM #300624) and Creatine Transporter Deficiency (CTD, #300352) are the two most common causes of X-linked intellectual disability. FXS and CTD affect hemizygous males and with highly variable severity heterozygous females. Both these neurodevelopmental disorders (NDDs) have a dramatic impact on the family quality of life and the health-care system. These disorders share common clinical traits, including intellectual disability, autistic-like features, behavioural and mood alterations and seizures. Brain anatomy appears largely normal, suggesting that functional deficits result from subtle changes in synaptic connectivity. Moreover, common physiological mechanisms related to brain energetics might concur to the pathophysiology of FXS and CTD. Indeed, FMR1 and SLC6A8 are directly involved in the regulation of metabolism and the loss-of-function of both genes leads to a disruption of the mitochondrial network.
There is no cure for these disorders and the efficacy study of potential treatments is hindered by the scarcity of unbiased, quantitative, non-invasive biomarkers for monitoring brain function.
Read more
This is a critical problem, since the often-used phenotypic observation of behavioural endpoints to score NDDs such as FXS and CTD is highly prone to subjective bias. For successful clinical trials, the availability of objective readouts is crucial to evaluate the therapeutic response to new drugs. There are multiple techniques to visualize neural circuit activity in the living brain. Interestingly, FXS and CTD are the only two NDDs that at preclinical level show an abnormally large hemodynamic response to sensory stimulation in functional imaging studies of intrinsic optical signals.
The objective of this project is to exploit optical imaging techniques to devise a measurable and non-invasive biomarker of brain function in FXS and CTD. Since a disruption of brain energy metabolism is a major disease mechanism linking these disorders, we hypothesized that the assessment of the cerebral blood flow and oxygen consumption represents a sensitive readout for quantifying functional alterations of neural circuits.
Functional near-infrared spectroscopy (fNIRS), allows quantifying changes of hemoglobin species and local blood flow in the cerebral cortex of humans, providing an indirect measure of neuronal activity. In the clinical framework, this blood-oxygen-level-dependent signal is similar to that detected with functional MRI (fMRI). However, fNIRS has the advantage of being completely non-invasive, low-cost, portable, noiseless, endowed with high experimental flexibility and easy to implement in both laboratory and clinical settings. Moreover, fNIRS is more tolerant to motion artifacts than fMRI, and robust methods for motion detection/correction allow to image very young children without sedation. These methodological strengths make fNIRS as an outstanding choice for investigating neural circuits in clinically relevant populations at the very-low cost. Although introduced into the clinical care almost 40 years ago, fNIRS gained much popularity in the study of brain development and NDDs only recently. To date, however, fNIRS has been used primarily to investigate the typical maturation of speech perception and language, sensory and motor functions, social communication and interaction, object and action processing in toddlers and children.
In this proposal, the investigators hypothesize that by combining the above-mentioned strengths of fNIRS to the clinical study of several cognitive and motor parameters, the investigators can define unique "fNIRS signatures" for FXS and CTD as brain biomarkers for the diagnosis and the assessment of treatment outcomes. Since the measurement of visual responses has been introduced as a quantitative method to assess brain function in NDDs, the investigators will test the value of visually-evoked fNIRS signals in classifying patients and predicting symptom severity in the FXS and CTD clinical population. Preliminary data in the mouse models of CTD and FXS strongly suggest that visual hemodynamic responses (vHDR) are markedly altered in the occipital cortex of mutant animals. Morever, the investigators will use a standardized procedure with high entertaining value to measure vHDR in the occipital cortex of children.
- Being tested
- Clinical assessment, Parental questionnaires, Cognitive assessment, Reasoning assessment, fNIRS assessement
- Keywords
- Fragile X syndrome, Optical imaging, brain function, Creatine transporter, cognitive function, reasoning tasks
- Medical subject headings
- Fragile X Syndrome, Creatine deficiency, X-linked
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical assessmentOther
Clinical examination including Medical history, developmental trajectory, epilepsy history, ASD symptoms, clinical examination at the inclusion visit by a neuropediatrist
Parental questionnairesOther
Parental questionnaires including Vineland-2, ABC, CBCL, PPD-MRS, SRS-2 and BRIEF completed at the inclusion visit
Cognitive assessmentOther
Cognitive assessment including Leiter-3, PPVT 5, EVT 3 completed at the inclusion visit
Reasoning assessmentOther
Simple reasoning tasks on tablets performed at the inclusion visit.
fNIRS assessementDevice
Imaging session using fNIRS (NIRSport 8x8, NIRx Medical Technologies LLC, Berlin, Germany) performed at the inclusion visit.
| Study group | Role | What they receive |
|---|---|---|
| Male CTD (Creatine Transporter Deficiency ) patients | Other | Male CTD patients having a confirmed mutation in the SLC6A8 gene, aged > 5 to < 35 years. Receives: Other: Clinical assessment; Other: Parental questionnaires; Other: Cognitive assessment; Other: Reasoning assessment; Device: fNIRS assessement |
| FXS (Fragile X Syndrome) patients | Other | Male FXS patients having a confirmed full mutation in the FMR1 gene (>200 GCC repeats), aged > 5 to < 35 years. Receives: Other: Clinical assessment; Other: Reasoning assessment; Device: fNIRS assessement |
| Sex and Chronological age-matched male controls | Other | Male aged > 5 to < 35 years. Receives: Other: Clinical assessment; Other: Parental questionnaires; Other: Cognitive assessment; Other: Reasoning assessment; Device: fNIRS assessement |
| Female CTD (Creatine Transporter Deficiency ) patients | Other | Female CTD patients having a confirmed mutation in the SLC6A8 gene, aged > 5 to < 60 years. Receives: Other: Clinical assessment; Other: Parental questionnaires; Other: Cognitive assessment; Other: Reasoning assessment; Device: fNIRS assessement |
| Sex and Chronological age-matched female controls | Other | Female aged > 5 to < 60 years. Receives: Other: Clinical assessment; Other: Parental questionnaires; Other: Cognitive assessment; Other: Reasoning assessment; Device: fNIRS assessement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amplitude of the visual hemodynamic response
Cortical hemodynamic activity data recorded via fNIRS imaging in response to visual stimulation (task-evoked) using a cartoon-based stimulus. Measure of the amplitude of the peak response to viewing radial checkerboard blended with the animated cartoon for total Hb, OxyHb and DeoxyHb concentration change.
Measured: Inclusion visit
Latency of the visual hemodynamic response
Cortical hemodynamic activity data recorded via fNIRS imaging in response to visual stimulation (task-evoked) using a cartoon-based stimulus. Measure of the latency of the peak response to viewing radial checkerboard blended with the animated cartoon for total Hb, OxyHb and DeoxyHb concentration change.
Measured: Inclusion visit
Secondary outcomes (16)
Clinical Endpoints_Presence of epilepsy
Presence of epilepsy
Measured: Inclusion visit
Clinical Endpoints_Type of epilepsy
Type of epilepsy
Measured: Inclusion visit
Clinical Endpoints_Treatment of epilepsy
Antiepileptic treatment (if any)
Measured: Inclusion visit
Clinical endpoints_Developmental trajectory
Age at walking, Age at first words, Age at 2 words association, Age at first sentences
Measured: Inclusion visit
Clinical endpoints_Autism spectrum disorder (ASD)
Autism spectrum disorder (ASD) diagnosis (using DSM5 criteria)
Measured: Inclusion visit
Cognitive assessment with Leiter 3 scale
Score of the cognitive assessment obtained with the Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests)
Measured: Inclusion visit
Cognitive assessment with Bayley 4 scale
Score of the cognitive assessment obtained with Bayley 4 scale (if Leiter 3 scale is not possible)
Measured: Inclusion visit
Language assessment with the PPVT-5 test
Score obtained with the PPVT-5 (Peabody Picture Vocabulary Test Fifth Edition) test for receptive vocabulary
Measured: Inclusion visit
Language assessment with the EVT-3 test
Score obtained with the EVT-3 (Expressive Vocabulary Test third edition) test for expressive vocabulary.
Measured: Inclusion visit
Reasoning tasks
Simple reasoning tasks on tablet (with four difficulty levels, A to D: match-to-sample task, categorization task, analogical reasoning task, implicit rules tasks). Reaction Time (RT) and Error Rate (ER) will be anayzed for each of the four reasoning tasks. The RT is defined as the time elapsing between the display of the image and the time when the subject selected one of the two answers.
Measured: Inclusion visit
Parental questionnaires to assess adaptive abilities (Vineland 2)
Parental questionnaires to assess adaptive abilities (Vineland 2)
Measured: Inclusion visit
Parental questionnaires to assess behavioral disorder (ABC 2)
Parental questionnaires to assess behavioral disorder (ABC 2)
Measured: Inclusion visit
Parental questionnaires to assess behavioral disorder (CBCL)
Parental questionnaires to assess behavioral disorder (CBCL)
Measured: Inclusion visit
Parental questionnaires to assess autistic features (PDD-MRS)
Parental questionnaires to assess autistic features (PDD-MRS)
Measured: Inclusion visit
Parental questionnaires to assess autistic features (SRS2)
Parental questionnaires to assess autistic features (SRS2)
Measured: Inclusion visit
Parental questionnaires to assess executive functions (BRIEF)
Parental questionnaires to assess executive functions (BRIEF)
Measured: Inclusion visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2025
- Study start30 Mar 2026
- Primary completionMar 2029 (estimated)
- Study completionMar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fragile X Syndrome (FXS)Studies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a multicentric prospective, cross-sectional case control study to determine biomarkers to be used in future clinical trials in CTD and FXS patients.
- Masking
- None (open label)
- Enrolment
- 118 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06868979
- Sponsor's protocol ID
- 69HCL23_0409
- Other IDs
- 2024-A01730-47
- Acronym
- IMAGINER
- Status last verified
- May 2026
- First submitted
- 14 Feb 2025
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optical Imaging as a Diagnostic Tool for Monitoring Brain Function in X-linked Rare Disorders
- ClinicalTrials.gov ID
- NCT06868979
- Acronym / sponsor ID
- IMAGINER / 69HCL23_0409
- Keywords
- Fragile X syndrome, Optical imaging, brain function, Creatine transporter, cognitive function, reasoning tasks
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 118 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 30 Mar 2026 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2029 (estimated)
- First posted
- 11 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fragile X syndrome (FXS, OMIM #300624) and Creatine Transporter Deficiency (CTD, #300352) are the two most common causes of X-linked intellectual disability. FXS and CTD affect hemizygous males and with highly variable severity heterozygous females. Both these neurodevelopmental disorders (NDDs) have a dramatic impact on the family quality of life and the health-care system. These disorders share common clinical traits, including intellectual disability, autistic-like features, behavioural and mood alterations and seizures. Brain anatomy appears largely normal, suggesting that functional deficits result from subtle changes in synaptic connectivity. Moreover, common physiological mechanisms related to brain energetics might concur to the pathophysiology of FXS and CTD. Indeed, FMR1 and SLC6A8 are directly involved in the regulation of metabolism and the loss-of-function of both genes leads to a disruption of the mitochondrial network.
There is no cure for these disorders and the efficacy study of potential treatments is hindered by the scarcity of unbiased, quantitative, non-invasive biomarkers for monitoring brain function.
This is a critical problem, since the often-used phenotypic observation of behavioural endpoints to score NDDs such as FXS and CTD is highly prone to subjective bias. For successful clinical trials, the availability of objective readouts is crucial to evaluate the therapeutic response to new drugs. There are multiple techniques to visualize neural circuit activity in the living brain. Interestingly, FXS and CTD are the only two NDDs that at preclinical level show an abnormally large hemodynamic response to sensory stimulation in functional imaging studies of intrinsic optical signals.
The objective of this project is to exploit optical imaging techniques to devise a measurable and non-invasive biomarker of brain function in FXS and CTD. Since a disruption of brain energy metabolism is a major disease mechanism linking these disorders, we hypothesized that the assessment of the cerebral blood flow and oxygen consumption represents a sensitive readout for quantifying functional alterations of neural circuits.
Functional near-infrared spectroscopy (fNIRS), allows quantifying changes of hemoglobin species and local blood flow in the cerebral cortex of humans, providing an indirect measure of neuronal activity. In the clinical framework, this blood-oxygen-level-dependent signal is similar to that detected with functional MRI (fMRI). However, fNIRS has the advantage of being completely non-invasive, low-cost, portable, noiseless, endowed with high experimental flexibility and easy to implement in both laboratory and clinical settings. Moreover, fNIRS is more tolerant to motion artifacts than fMRI, and robust methods for motion detection/correction allow to image very young children without sedation. These methodological strengths make fNIRS as an outstanding choice for investigating neural circuits in clinically relevant populations at the very-low cost. Although introduced into the clinical care almost 40 years ago, fNIRS gained much popularity in the study of brain development and NDDs only recently. To date, however, fNIRS has been used primarily to investigate the typical maturation of speech perception and language, sensory and motor functions, social communication and interaction, object and action processing in toddlers and children.
In this proposal, the investigators hypothesize that by combining the above-mentioned strengths of fNIRS to the clinical study of several cognitive and motor parameters, the investigators can define unique "fNIRS signatures" for FXS and CTD as brain biomarkers for the diagnosis and the assessment of treatment outcomes. Since the measurement of visual responses has been introduced as a quantitative method to assess brain function in NDDs, the investigators will test the value of visually-evoked fNIRS signals in classifying patients and predicting symptom severity in the FXS and CTD clinical population. Preliminary data in the mouse models of CTD and FXS strongly suggest that visual hemodynamic responses (vHDR) are markedly altered in the occipital cortex of mutant animals. Morever, the investigators will use a standardized procedure with high entertaining value to measure vHDR in the occipital cortex of children.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 5
- Model description
- This is a multicentric prospective, cross-sectional case control study to determine biomarkers to be used in future clinical trials in CTD and FXS patients.
| Arm | Type | Receives |
|---|---|---|
| Male CTD (Creatine Transporter Deficiency ) patients | Other | Other: Clinical assessment, Other: Parental questionnaires, Other: Cognitive assessment, Other: Reasoning assessment, Device: fNIRS assessementMale CTD patients having a confirmed mutation in the SLC6A8 gene, aged > 5 to < 35 years. |
| FXS (Fragile X Syndrome) patients | Other | Other: Clinical assessment, Other: Reasoning assessment, Device: fNIRS assessementMale FXS patients having a confirmed full mutation in the FMR1 gene (>200 GCC repeats), aged > 5 to < 35 years. |
| Sex and Chronological age-matched male controls | Other | Other: Clinical assessment, Other: Parental questionnaires, Other: Cognitive assessment, Other: Reasoning assessment, Device: fNIRS assessementMale aged > 5 to < 35 years. |
| Female CTD (Creatine Transporter Deficiency ) patients | Other | Other: Clinical assessment, Other: Parental questionnaires, Other: Cognitive assessment, Other: Reasoning assessment, Device: fNIRS assessementFemale CTD patients having a confirmed mutation in the SLC6A8 gene, aged > 5 to < 60 years. |
| Sex and Chronological age-matched female controls | Other | Other: Clinical assessment, Other: Parental questionnaires, Other: Cognitive assessment, Other: Reasoning assessment, Device: fNIRS assessementFemale aged > 5 to < 60 years. |
Who may qualify
- Ages
- 5 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (33 listed)
- male
- having a confirmed mutation in the SLC6A8 gene
- ≥ 5 to ≤ 35 years old
- whose maternal language is French,
- having signed the informed consent and/or for whom parents (for children)/legal guardian (for protected adults) have signed the informed consent.
Key exclusion criteria (12 listed)
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
- Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
- Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.
- Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical assessmentClinical examination including Medical history, developmental trajectory, epilepsy history, ASD symptoms, clinical examination at the inclusion visit by a neuropediatrist | Other | FXS (Fragile X Syndrome) patients, Female CTD (Creatine Transporter Deficiency ) patients, Male CTD (Creatine Transporter Deficiency ) patients, Sex and Chronological age-matched female controls, Sex and Chronological age-matched male controls |
| Parental questionnairesParental questionnaires including Vineland-2, ABC, CBCL, PPD-MRS, SRS-2 and BRIEF completed at the inclusion visit | Other | Female CTD (Creatine Transporter Deficiency ) patients, Male CTD (Creatine Transporter Deficiency ) patients, Sex and Chronological age-matched female controls, Sex and Chronological age-matched male controls |
| Cognitive assessmentCognitive assessment including Leiter-3, PPVT 5, EVT 3 completed at the inclusion visit | Other | Female CTD (Creatine Transporter Deficiency ) patients, Male CTD (Creatine Transporter Deficiency ) patients, Sex and Chronological age-matched female controls, Sex and Chronological age-matched male controls |
| Reasoning assessmentSimple reasoning tasks on tablets performed at the inclusion visit. | Other | FXS (Fragile X Syndrome) patients, Female CTD (Creatine Transporter Deficiency ) patients, Male CTD (Creatine Transporter Deficiency ) patients, Sex and Chronological age-matched female controls, Sex and Chronological age-matched male controls |
| fNIRS assessementImaging session using fNIRS (NIRSport 8x8, NIRx Medical Technologies LLC, Berlin, Germany) performed at the inclusion visit. | Device | FXS (Fragile X Syndrome) patients, Female CTD (Creatine Transporter Deficiency ) patients, Male CTD (Creatine Transporter Deficiency ) patients, Sex and Chronological age-matched female controls, Sex and Chronological age-matched male controls |
Primary outcome
Amplitude of the visual hemodynamic response
Time frame: Inclusion visit
Cortical hemodynamic activity data recorded via fNIRS imaging in response to visual stimulation (task-evoked) using a cartoon-based stimulus. Measure of the amplitude of the peak response to viewing radial checkerboard blended with the animated cartoon for total Hb, OxyHb and DeoxyHb concentration change.
Latency of the visual hemodynamic response
Time frame: Inclusion visit
Cortical hemodynamic activity data recorded via fNIRS imaging in response to visual stimulation (task-evoked) using a cartoon-based stimulus. Measure of the latency of the peak response to viewing radial checkerboard blended with the animated cartoon for total Hb, OxyHb and DeoxyHb concentration change.
16 secondary outcomes
Clinical Endpoints_Presence of epilepsy
Time frame: Inclusion visit
Clinical Endpoints_Type of epilepsy
Time frame: Inclusion visit
Clinical Endpoints_Treatment of epilepsy
Time frame: Inclusion visit
Clinical endpoints_Developmental trajectory
Time frame: Inclusion visit
Clinical endpoints_Autism spectrum disorder (ASD)
Time frame: Inclusion visit
Cognitive assessment with Leiter 3 scale
Time frame: Inclusion visit
Cognitive assessment with Bayley 4 scale
Time frame: Inclusion visit
Language assessment with the PPVT-5 test
Time frame: Inclusion visit
Language assessment with the EVT-3 test
Time frame: Inclusion visit
Reasoning tasks
Time frame: Inclusion visit
Parental questionnaires to assess adaptive abilities (Vineland 2)
Time frame: Inclusion visit
Parental questionnaires to assess behavioral disorder (ABC 2)
Time frame: Inclusion visit
Parental questionnaires to assess behavioral disorder (CBCL)
Time frame: Inclusion visit
Parental questionnaires to assess autistic features (PDD-MRS)
Time frame: Inclusion visit
Parental questionnaires to assess autistic features (SRS2)
Time frame: Inclusion visit
Parental questionnaires to assess executive functions (BRIEF)
Time frame: Inclusion visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
Related trials for Fragile X Syndrome (FXS)
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Not yet recruitingPhase 2/3
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
RecruitingPhase 2
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Fragile X Syndrome
Active, not recruiting
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis
RecruitingPhase 2
Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome
Fragile X Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical assessment, Parental questionnaires and Cognitive assessment in people with Fragile X Syndrome (FXS) and Creatine Transporter Deficiency, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 33 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aurore CURIE, Dr (+336 70 62 69 76, Aurore.curie@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amplitude of the visual hemodynamic response (time frame: Inclusion visit). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.